Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30697897 | 1.00 | LMNA (0.52) | LMNAHPGDAHRCYP2A6NOS1 | |
| SCHEMBL10246 | 0.83 | CYP2A6 (0.59) | LMNAHPGDAHRCYP2A6NOS1 | |
| SCHEMBL890079 | 0.77 | DAO (0.55) | CYP2A6KEAP1ALDH1A1AXLITK | |
| SCHEMBL30807019 | 0.77 | DAO (0.55) | CYP2A6KEAP1ALDH1A1AXLITK | |
| SCHEMBL3364704 | 0.77 | AHR (0.50) | AHRCYP2A6NOS1METAP2DYRK1A | |
| SCHEMBL17433431 | 0.77 | ITK (0.51) | AHRCYP2A6NOS1METAP2DYRK1A | |
| SCHEMBL29892803 | 0.76 | BRD4 (0.59) | LMNAHPGDAHRMETAP2DYRK1A | |
| SCHEMBL2490392 | 0.74 | AHR (0.47) | AHRCYP2A6NOS1METAP2DYRK1A | |
| SCHEMBL2993745 | 0.74 | KEAP1 (0.52) | AHRCYP2A6KEAP1AXLITK | |
| SCHEMBL614723 | 0.74 | LMNA (0.56) | LMNAHPGDAHRCYP2A6NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015351-A1 | METHODS AND COMPOUNDS FOR INHIBITING MKK7 ENZYMES | AXONIS THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2025243317-A1 | SUBSTITUTED BICYCLIC SULFONAMIDE DERIVATIVES AS MODULATORS OF CBL-B | JUBILANT BIOSYS LIMITED (IN) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250263760-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| CN-120202211-A | Cyclic compounds having selective KRAS inhibition over HRAS and NRAS | 中外制药株式会社 | 2025-06-24 | — | — | CN | disclosed |
| US-12319698-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| US-4403791-A | Carbonless duplicating and marking systems | STERLING DRUG INC. (US) | 1983-09-13 | — | — | US | disclosed |
| US-4377698-A | 2,4 Bis(2-indolyl-3)-4-oxobutanoic acids | STERLING DRUG INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4351768-A | CARBONLESS, DUPLICATION, INDOLE DYES | STERLING DRUG INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4322352-A | Indolyl phthalide compounds | STERLING DRUG INC. (US) | 1982-03-30 | — | — | US | disclosed |
| US-4307018-A | CHROMOGENS FOR COPYING SYSTEMS | STERLING DRUG INC. (US) | 1981-12-22 | — | — | US | disclosed |
| US-4275121-A | Carbonless duplicating and marking systems utilizing indolyl-substituted furanone color formers | STERLING DRUG INC. (US) | 1981-06-23 | — | — | US | disclosed |
| US-4257954-A | INDOLYL-PHENYLSULFONYL-PHENYL METHANE | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4251446-A | COLOR PRECURSORS | STERLING DRUG INC. (US) | 1981-02-17 | — | — | US | disclosed |
| US-4189171-A | PRESSURE SENSITIVE, THERMAL AND HECTOGRAPHIC SYSTEMS | STERLING DRUG INC. (US) | 1980-02-19 | — | — | US | disclosed |
| US-4075224-A | 3,5-Bis (indolyl)-5-(indolyl)-2(5H)-furanones | STERLING DRUG INC. (US) | 1978-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319698-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | LMNA 1575/4885HPGD 3178/4885AHR 1922/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | LMNA 4471/4885HPGD 1726/4885AHR 1109/4885 |
| US-20260015351-A1 | METHODS AND COMPOUNDS FOR INHIBITING MKK7 ENZYMES | PRKCSH, MAPK7, PRKCB | LMNA 1835/4885HPGD 2858/4885AHR 2920/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | LMNA 4471/4885HPGD 1726/4885AHR 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.